All In Biotech

Drug Trial Radar · NCT01631617

Effects of Treatments on Atopic Dermatitis

Effects of Treatments on the Microbiome in Healthy Volunteers and Patients With Atopic Dermatitis

Last checked: Nov 20, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 130 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

130

Planned (sponsor's estimate)

Start

Sep 18, 2012

Primary completion

Jan 1, 2027

Study completion Jan 1, 2027

Sponsor

Sponsor type
NIH
First posted
Jun 29, 2012

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Single (investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 2 years, up to 50 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Background: \- Atopic dermatitis, or eczema, is a chronic skin disorder. Patients sometimes have infections with S. aureus bacteria. Researchers want to study how eczema treatments affect the number and the type of bacteria on the skin. Objectives: \- To study the effect of eczema treatments on skin bacteria. Eligibility: * Individuals between 2 and 25 years of age who have moderate to severe atopic dermatitis. * Healthy volunteers between 18 and 40 years of age with no history of eczema. Design: * Participants will be screened with a physical exam and medical history. Research samples will be collected. Skin biopsies may also be performed. * All participants will be assigned to one of several study groups. * Healthy volunteers must not have taken antibiotics in the year before the start of the study. * All participants will have regular study visits during their 1-year participation. More research samples will be collected at these visits. * Healthy volunteers may be asked to come in for a one-time follow up after the 1 year mark.

Conditions

  • Eczema
  • Dermatitis
  • Skin Diseases, Genetic
  • Dermatitis, Atopic
  • Skin Diseases

Interventions

  • Trimethoprim/sulfamethoxazole (TMP/SMZ)Drug

    800/160 orally every 12 hours for 14 days

  • CephalexinDrug

    500 mg orally every 8 hours for 14 days

  • DoxycyclineDrug

    20 mg orally every 12 hours for 56 days or 100 mg orally every 12 hours for 56 days

  • Sodium hypochloriteOther

    6 % dilute bleach

  • Placebo capsulesOther

    Capsule orally every 8 hours daily for 14 days

  • Placebo Sodium hypochloriteOther

    Three times a week for 14 days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Characterize microbiome alterationsTime frame: 2 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • National Institutes of Health Clinical Center

    Bethesda, Maryland · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.